Regulations & quality and bioproduction

Level 2 -

Annex 1: sterile filtration and integrity testing

Presentation

Why participate?

Identify the regulatory changes concerning sterile filtration following the implementation of the new Annex 1 of the GMP guidelines.
Ultimately, ensure compliance with the new regulations and be able to justify your filtration-related decisions.

Training Context:

The new Annex 1 was published on August 25, 2022, and came into force on August 25, 2023. While the revised document expanded from 16 to 59 pages and brings significant clarification, many questions remain — especially concerning sterile filtration, including differential pressure monitoring and the implementation of the Pre-Use Post-Sterilization Integrity Test (PUPSIT).
PUPSIT has been one of the most debated topics due to the complexity of its implementation. The SFQRM discussion group from the BPOG-PDA consortium has published several recommendations outlining the pros, cons, and associated risks.

Learning objectives

  • Understand the impact on processes and their validation
  • Determine which filters to test, when, where, and how
  • Distinguish between a regulatory test and an industrial risk-reduction test
  • Understand the implications of PUPSIT
  • Learn how to reduce the risk of false compliance related to PUPSIT
  • Understand the guidance published by the Sterile Filtration Quality Risk Management (SFQRM) group of the BPOG-PDA consortium

Teaching methods

Interactive teaching, real-life examples, experience sharing

Audience

Quality assurance, sterility assurance, regulatory compliance, managers, production supervisors

Prerequisites

Prerequisites: knowledge of quality assurance, sterility, and regulatory compliance

Duration

1 day, 7 hours

Price

750 € HT (Public)
600 € HT (Membre)
300 € HT (Académique)

Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.

Trainers

Catalogue de formations-MabDesign-2023.pdf (25)

Magnus

STERING

Senior Product and Project Manager
Sartorius

Rating

There is no rating available because this training session was never carried out.

The benefits of our courses

  • Personalized support
  • Skills assessment
  • Certificate of completion
  • Training quality evaluation
  • Accessible to people with disabilities (please contact us)

How to access and deadlines

Registering online or by e-mail is a pre-registration. We will process your request within one week:

  • Contact by e-mail or telephone
  • Sending of administrative and educational documents: training agreement, training programme and positioning questionnaire.

Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.

When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.

For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr

Jean-Roch Fabreguettes

MEARY

Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris

Jean-Roch Fabreguettes est un spécialiste de la recherche translationnelle et des phases précoces de développement clinique des médicaments de thérapie innovantes (MTI). Pharmacien, titulaire d’un doctorat de l’Université de Montpellier 1, il a travaillé plus de 25 ans dans le domaine et a contribué, pour des équipes académiques comme pour des start-ups, à la réalisation de plus de 30 programmes de recherche sur différents types de MTI : thérapie génique in vivo ou ex vivo, thérapie cellulaire, ingénierie tissulaire… Il est actuellement Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris. Le centre MEARY est une plateforme de l’Assistance Publique – Hôpitaux de Paris (AP-HP), dédiée à la fabrication de médicament de thérapie innovante expérimentaux. Laboratoire membre de l’ISCT, il est autorisé par l’ANSM et dispose d’un certificat GMP. A ce titre Jean-Roch Fabreguettes est impliqué dans le développement clinique et la fabrication de nombreux MTI : CAR-T cells, lymphocytes T régulateurs, cellules stromales mésenchymateuses…

Précédemment, Jean-Roch Fabreguettes a été expert Qualité (CMC) auprès de l’ANSM durant 9 ans et a conseillé différentes sociétés de biotechnologies. Il est un intervenant régulier pour l’Université Paris Cité et un membre actif de l’ISCT et de réseaux nationaux et internationaux sur les MTI (UNI-TC, Join4ATMP).